Omega-3 fatty acids and metabolic partitioning of fatty acids within the liver in the context of nonalcoholic fatty liver disease

Current Opinion in Clinical Nutrition & Metabolic Care, Год журнала: 2022, Номер 25(4), С. 248 - 255

Опубликована: Июнь 28, 2022

Nonalcoholic fatty liver disease (NAFLD) is now the most prevalent form of globally, affecting about 25% world's adult population. It more common in those living with obesity, where it may affect as many 80% individuals. The aim this article to describe recent human studies evaluating influence omega-3 acids on de novo lipogenesis (DNL) and hepatic acid partitioning between incorporation into triacylglycerols (TAGs) β-oxidation, discuss relevance these effects context NAFLD, provide an overview mechanisms that might be involved.The eicosapentaenoic (EPA) docosahexaenoic (DHA) decrease DNL partition away from TAG synthesis toward β-oxidation. EPA DHA multiple transcription factors resulting down-regulation pathway upregulation net result decreased accumulation lowering circulating concentrations. Human trials demonstrate can fat patients NAFLD.Increased intake reduce likelihood could used NAFLD.

Язык: Английский

---

Acacetin Protects against Non-Alcoholic Fatty Liver Disease by Regulating Lipid Accumulation and Inflammation in Mice

International Journal of Molecular Sciences, Год журнала: 2022, Номер 23(9), С. 4687 - 4687

Опубликована: Апрель 23, 2022

We previously demonstrated that acacetin reduces adipogenesis in adipocytes, and decreases lipid accumulation visceral adipocyte tissue. Here we investigated whether regulated the mechanisms of lipogenesis inflammation non-alcoholic fatty liver disease (NAFLD) obese mice. Male C57BL/6 mice were fed a high-fat diet (HFD), then administered by intraperitoneal injection. Acacetin reduced body weight Acacetin-treated exhibited decreased accumulation, increased glycogen improved hepatocyte steatosis. triglycerides total cholesterol serum. low-density lipoprotein leptin concentrations, but high-density adiponectin levels effectively weakened gene expressions transcription factors related to lipogenesis, promoted genes lipolysis acid β-oxidation liver. also inflammation-related cytokines serum Oleic induced murine FL83B hepatocytes, effects treatment indicated may regulate metabolism through AMPK pathway. protect against hepatic steatosis modulating expression.

Язык: Английский

---

Direct and systemic actions of growth hormone receptor (GHR)-signaling on hepatic glycolysis, de novo lipogenesis and insulin sensitivity, associated with steatosis

Metabolism, Год журнала: 2023, Номер 144, С. 155589 - 155589

Опубликована: Май 13, 2023

Язык: Английский

---

New Insights into AMPK, as a Potential Therapeutic Target in Metabolic Dysfunction-Associated Steatotic Liver Disease and Hepatic Fibrosis

Biomolecules & Therapeutics, Год журнала: 2024, Номер unknown

Опубликована: Дек. 20, 2024

AMP-activated protein kinase (AMPK) activators have garnered significant attention for their potential to prevent the progression of metabolic dysfunction-associated steatotic liver disease (MASLD) into fibrosis and fundamentally improve function. The broad spectrum pathways regulated by AMPK makes them promising alternatives conventional replacement therapies limited pharmacological treatments currently available. In this study, we aim illustrate newly detailed multiple mechanisms MASLD based on multiple-hit hypothesis. This model posits that impaired lipid metabolism, combined with insulin resistance imbalance, initiates inflammatory cascades, gut dysbiosis, accumulation toxic metabolites, ultimately promoting accelerating irreversible hepatocellular carcinoma (HCC). plays a multifaceted protective role against these pathological conditions regulating several key downstream signaling pathways. It regulates biological effectors critical responses, such as SIRT1, Nrf2, mTOR, TGF-β, through complex interrelated mechanisms. Due intricate connections, AMPK's is pivotal in managing disorders. review, demonstrate specific roles its related Several agents directly activate binding agonists, while some others indirectly modulating upstream molecules, including adiponectin, LKB1, AMP: ATP ratio. As can target each stage progression, development offers immense expand therapeutic strategies diseases MASH, MASLD, fibrosis.

Язык: Английский

---

Efficacy and underlying mechanisms of berberine against lipid metabolic diseases: a review

Frontiers in Pharmacology, Год журнала: 2023, Номер 14

Опубликована: Ноя. 15, 2023

Lipid-lowering therapy is an important tool for the treatment of lipid metabolic diseases, which are increasing in prevalence. However, failure conventional lipid-lowering drugs to achieve desired efficacy some patients, and side-effects these drug regimens, highlight urgent need novel drugs. The liver intestine production removal endogenous exogenous lipids, respectively, have impact on circulating levels. Elevated lipids predisposes individual deposition vascular wall, affecting function. Berberine (BBR) modulates clearance by regulating cellular targets such as cluster differentiation 36 (CD36), acetyl-CoA carboxylase (ACC), microsomal triglyceride transfer protein (MTTP), scavenger receptor class B type 1 (SR-BI), low-density lipoprotein (LDLR), ATP-binding cassette transporter A1 (ABCA1). It influences intestinal synthesis metabolism modulating gut microbiota composition metabolism. Finally, BBR maintains function targeting proteins endothelial nitric oxide synthase (eNOS) lectin-like oxidized receptor-1 (LOX-1). This paper elucidates summarizes pharmacological mechanisms berberine diseases from a multi-organ (liver, intestine, system) multi-target perspective.

Язык: Английский

---